The recommendation follows the ‘consistent, significant improvements’ in median progression-free survival and overall response rates when using Piqray in combination with Faslodex.
Breast cancer is the most common type of cancer in the UK, with around 55,000 women diagnosed each year, and endocrine resistance affecting approximately 40% of HR+/HER2- advanced breast cancer patients.
Commenting on the recommendation, Nicolò Battisti, medical oncologist at The Royal Marsden NHS Foundation Trust, said: “NICE’s recommendation is an important development in the treatment of advanced breast cancer, an area where there is an urgent need for innovation to improve clinical and patient outcomes…
